These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16304179)

  • 21. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery.
    von Baum H; Böttcher S; Hoffmann H; Sonntag HG
    J Antimicrob Chemother; 2001 May; 47(5):729-30. PubMed ID: 11328803
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of cardiopulmonary bypass on regional antibiotic penetration into lung tissue.
    Hutschala D; Skhirtladze K; Kinstner C; Zeitlinger M; Wisser W; Jaeger W; Hoeferl M; Müller M; Tschernko E
    Antimicrob Agents Chemother; 2013 Jul; 57(7):2996-3002. PubMed ID: 23587954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.
    Destache CJ; Pakiz CB; Larsen C; Owens H; Dash AK
    J Antimicrob Chemother; 2001 May; 47(5):611-5. PubMed ID: 11328772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo.
    Tanaka M; Ono C; Yamada M
    J Pharm Pharmacol; 2004 Apr; 56(4):463-9. PubMed ID: 15099441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
    Paladino JA; Sunderlin JL; Forrest A; Schentag JJ
    J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections.
    Guillaume M; Garraffo R; Bensalem M; Janssen C; Bland S; Gaillat J; Bru JP
    Med Mal Infect; 2012 Sep; 42(9):414-20. PubMed ID: 22944286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
    Pea F; Di Qual E; Cusenza A; Brollo L; Baldassarre M; Furlanut M
    Clin Pharmacokinet; 2003; 42(6):589-98. PubMed ID: 12793843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery.
    Gascón AR; Campo E; Hernández RM; Calvo B; Errasti J; Pedraz Muñoz JL
    J Clin Pharmacol; 2000 Aug; 40(8):869-74. PubMed ID: 10934671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
    Louie A; Fregeau C; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3325-30. PubMed ID: 19364849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
    Fukuda M; Yamada M; Kinoshita S; Inatomi T; Ohashi Y; Uno T; Shimazaki J; Satake Y; Maeda N; Hori Y; Nishida K; Kubota A; Nakazawa T; Shimomura Y
    Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Cazzola M; Matera MG; Donnarumma G; Tufano MA; Sanduzzi A; Marchetti F; Blasi F
    Chest; 2005 Oct; 128(4):2093-8. PubMed ID: 16236860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery.
    Holland EJ; McCarthy M; Holland S
    Curr Med Res Opin; 2007 Dec; 23(12):2955-60. PubMed ID: 17939882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.